In the secondary analysis, the significantly less conservative but clinically meaningful criterion of secure response (described being a 50% or more reduction in MADRS from baseline for two months) was used. In the patients who attained secure reaction, 25.eight% within the esketamine group and 57.six% within the placebo group relapsed, https://mickn360fjp9.wikipublicity.com/user